7210 Wareham Drive, Tampa, FL 33647
Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists […]
Zepbound Beats Wegovy for Weight Loss Read More »
November 20, 2024 Herbalife’s sales of weight management products in North America continue to decline, most likely due to strong competition from the GLP-1 weight loss drugs. Total U.S. sales for the 9 months ended Sept. 30, 2024 were down 7.9%, and North American sales represented 21% of the total. Total weight management sales from
Herbalife Weight Management Sales Continue Slide Read More »
Nov. 6, 2024 WW (Weight Watchers) reported results for the 3rd quarter 2024 today. “For over six decades, Weight Watchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to
Weight Watchers Reports 3rd Quarter Results Read More »
Nov. 4, 2024 Medifast reported Q3 results today. CEO Dan Chard said: “With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.” Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672
Medifast Reports 3rd Quarter Results Read More »
October 17, 2024 According to State Health, the telehealth GLP-1 boom wouldn’t be possible without clinicians willing to write prescriptions for those hundreds of thousands of patients. Companies are rarely transparent — with patients or the public — about the medical groups behind the screens. But a STAT examination found that just a handful of networks of
Invisible Medical Groups Are Behind GLP-1 Boom Read More »
Oct. 8, 2024 WW announced the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions. The new offering, starting at $129, enhances the Company’s holistic weight management program, which includes behavioral and clinical solutions with support from board-certified clinicians, registered dietitians, and the global Weight Watchers community. This
Weight Watchers Adds Compounded Meds Read More »
Sept. 27, 2024 WeightWatchers Board member Tara Comonte has been appointed Interim Chief Executive Officer. Ms. Comonte succeeds Sima Sistani, who departs from her role as Chief Executive Officer and as a member of the Board, effective today. “During her tenure, Ms. Sistani led the Company’s transformation to a modern digital health organization and extended
Weight Watchers CEO Departs Abruptly Read More »
Sept. 25, 2024 Lindora Clinics, a regional medical weight loss chain based in California, has recently begun franchising. As such, it has filed a 2024 FDD (Franchise Disclosure Document) that describes the franchise, its investment costs, etc. Lindora is a long-established company in the weight loss market, with a variety of weight loss programs, both
Lindora Clinics Franchise Is Well Diversified Read More »
Sept. 24, 2024 Marketdata LLC, DietBusinessWatch.com’s parent), estimates that the top competitors in the U.S. weight loss market lost at least $971 million in revenues last year, due to the juggernaut of GLP-1 medications. This is a huge transfer of sales from commercial and retail weight loss programs and product segments to medical programs. Here’s
Weight Loss Market’s Leaders Lost At Least $971 Million in 2023 Read More »
Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic. The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The
GLP-1 Drugs Market Update Read More »